quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:12:00·919d
NEWSRelease
Baudax Bio Inc. logo

Baudax Bio Announces Corporate Update; Co. Says Phase 1/2a Clinical Study Of TI-168 In Hemophilia A with FVIII Inhibitors Projected To Begin In Q1 2024

BXRX· Baudax Bio Inc.
Health Care
Original source

Companies

  • BXRX
    Baudax Bio Inc.
    Health Care

Related

  • SEC786d
    SEC Form 8-K filed by Baudax Bio Inc.
  • SEC798d
    SEC Form 25-NSE filed by Baudax Bio Inc.
  • 13D/G799d
    SEC Form SC 13G/A filed by Baudax Bio Inc. (Amendment)
  • 13D/G807d
    SEC Form SC 13G/A filed by Baudax Bio Inc. (Amendment)
  • SEC863d
    Baudax Bio Inc. filed SEC Form 8-K: Other Events
  • NEWS875d
    CORRECTION: BioCryst Pharmaceuticals Ticker is "BCRX
  • NEWS875d
    BioCryst Pharmaceuticals Updated Its Agreement With Torii Pharmaceutica For ORLADEYO In Japan; BioCryst Japan K.K. Responsible For All Commercial Promotion Activities And Torii Will Be Responsible For Hereditary Angioedema Disease Awareness Activities
  • SEC883d
    SEC Form 424B3 filed by Baudax Bio Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022